{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T19:54:21Z","timestamp":1761854061993,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"vor","delay-in-days":46,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.nefroe.2024.01.018","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T12:20:58Z","timestamp":1706185258000},"page":"91-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"S2","title":["Correlation of X chromosome inactivation with clinical presentation of Fabry disease in a case report"],"prefix":"10.1016","volume":"43","author":[{"given":"Pablo","family":"Rodr\u00edguez Doy\u00e1g\u00fcez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Furlano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabet","family":"Ars Criach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolanda","family":"Arce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Llu\u00eds","family":"Guirado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roser","family":"Torra Balcells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefroe.2024.01.018_bib0005","doi-asserted-by":"crossref","first-page":"7663","DOI":"10.3390\/ijms22147663","article-title":"X chromosome inactivation in carriers of Fabry disease: review and meta-analysis","volume":"22","author":"Viggiano","year":"2021","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.nefroe.2024.01.018_bib0010","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ekir.2019.11.013","article-title":"Current and investigational therapeutics for Fabry disease","volume":"5","author":"Felis","year":"2019","journal-title":"Kidney Int Rep."},{"key":"10.1016\/j.nefroe.2024.01.018_bib0015","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ndt\/gfab038","article-title":"Precision medicine in Fabry disease","volume":"36","author":"Lenders","year":"2021","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefroe.2024.01.018_bib0020","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol Genet Metab."},{"key":"10.1016\/j.nefroe.2024.01.018_bib0025","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","article-title":"European expert consensus statement on therapeutic goals in Fabry disease","volume":"124","author":"Wanner","year":"2018","journal-title":"Mol Genet Metab."},{"key":"10.1016\/j.nefroe.2024.01.018_bib0030","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.kint.2016.10.004","article-title":"Screening, diagnosis, and management of patients with Fabry disease: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"91","author":"Schiffmann","year":"2017","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefroe.2024.01.018_bib0035","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ymgme.2018.09.007","article-title":"The effect of enzyme replacement therapy on clinical outcomes in female patients with Fabry disease - a systematic literature review by a European panel of experts","volume":"126","author":"Germain","year":"2019","journal-title":"Mol Genet Metab."},{"key":"10.1016\/j.nefroe.2024.01.018_bib0040","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/sj.ejhg.5201452","article-title":"Male-to-male transmission of X-linked Alport syndrome in a boy with a 47. XXY karyotype","volume":"13","author":"Ars","year":"2005","journal-title":"Eur J Hum Genet."},{"key":"10.1016\/j.nefroe.2024.01.018_bib0045","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin Genet."},{"key":"10.1016\/j.nefroe.2024.01.018_bib0050","doi-asserted-by":"crossref","DOI":"10.1242\/dev.183095","article-title":"X chromosome inactivation in human development","volume":"147","author":"Patrat","year":"2020","journal-title":"Development."},{"key":"10.1016\/j.nefroe.2024.01.018_bib0055","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1681\/ASN.2008020198","article-title":"X inactivation, female mosaicism, and sex differences in renal diseases","volume":"19","author":"Migeon","year":"2008","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.nefroe.2024.01.018_bib0060","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/ajmg.a.62728","article-title":"Pitfalls of X-chromosome inactivation testing in females with Fabry disease","volume":"188","author":"\u0158eboun","year":"2022","journal-title":"Am J Med Genet A."},{"key":"10.1016\/j.nefroe.2024.01.018_bib0065","unstructured":"Ars E. Enfoque gen\u00e9tico de las enfermedades renales hereditarias. Laboratorio de Biolog\u00eda Molecular, Fundaci\u00f3 Puigvert, Instituto de Investigaciones Biom\u00e9dicas Sant Pau (IIB-Sant Pau), Universitat Aut\u00f2noma de Barcelona, REDINREN, Barcelona. Updated Feb 2021. Available from: www.nefrologiaaldia.org."},{"key":"10.1016\/j.nefroe.2024.01.018_bib0070","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1038\/s41436-020-0779-4","article-title":"X-linked diseases: susceptible females","volume":"22","author":"Migeon","year":"2020","journal-title":"Genet Med."},{"key":"10.1016\/j.nefroe.2024.01.018_bib0075","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.tcb.2018.05.005","article-title":"The role of Xist in X-chromosome dosage compensation","volume":"28","author":"Sahakyan","year":"2018","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.nefroe.2024.01.018_bib0080","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13059-015-0618-0","article-title":"The lncRNA Firre anchors the inactive X chromosome to the nucleolus by binding CTCF and maintains H3K27me3 methylation","volume":"16","author":"Yang","year":"2015","journal-title":"Genome Biol."},{"key":"10.1016\/j.nefroe.2024.01.018_bib0085","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/ng1705","article-title":"Dosage compensation of the active X chromosome in mammals","volume":"38","author":"Nguyen","year":"2006","journal-title":"Nat Genet."},{"key":"10.1016\/j.nefroe.2024.01.018_bib0090","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00412-008-0189-x","article-title":"ATRX marks the inactive X chromosome (Xi) in somatic cells and during imprinted X chromosome inactivation in trophoblast stem cells","volume":"118","author":"Baumann","year":"2009","journal-title":"Chromosoma."},{"key":"10.1016\/j.nefroe.2024.01.018_bib0095","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13148-021-01019-3","article-title":"DNA methylation impact on Fabry disease","volume":"13","author":"Di Risi","year":"2021","journal-title":"Clin Epigenetics."}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251424000282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251424000282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T19:51:34Z","timestamp":1761853894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2013251424000282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":19,"alternative-id":["S2013251424000282"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2024.01.018","relation":{},"ISSN":["2013-2514"],"issn-type":[{"type":"print","value":"2013-2514"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correlation of X chromosome inactivation with clinical presentation of Fabry disease in a case report","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2024.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Nefrolog\u00eda.","name":"copyright","label":"Copyright"}]}}